Murine Melanoma

Immunotherapy generates selective pressure for acquisition of immunogenic neoantigens in escape tumors
Jenny H Pan, Suman Vodnala, Robert L Eil, Zhiya Yu, Jared J Gartner, David Clever, Rahul Roychoudhuri, Shashank J Patel, Christopher A Klebanoff, Madhusudhanan Sukumar, Tori Yamamoto, Nicholas P Restifo

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P68; DOI: 10.1186/2051-1426-3-S2-P68
Combination of intravenously delivered cavatak (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and tumor rechallenge
Min Yuan, Yvonne Wong, Gough Au, Darren Shafren

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P342; DOI: 10.1186/2051-1426-3-S2-P342
In vivo depletion of CD25+ cells prior to LRAST increases therapeutic efficacy in a murine melanoma model
Julia R Kovács, Peter Rose, Louis Boon, Rudolf A Hatz, Hauke Winter, Natasja K van den Engel

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P51; DOI: 10.1186/2051-1426-2-S3-P51
Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model
Rikke B Holmgaard, Dmitriy Zamarin, David H Munn, Taha Merghoub, Jedd D Wolchok

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P212; DOI: 10.1186/2051-1426-2-S3-P212
P53. Effect of lymphodepletion and tumour on host and reconstituted regulatory T-cells in a model of murine melanoma
J Kovács, P Rose, RA Hatz, H Winter, NK van den Engel

Journal for ImmunoTherapy of Cancer Mar 2014, 2 (Suppl 2) P27; DOI: 10.1186/2051-1426-2-S2-P27

Log in using your username and password

Main menu

Log in using your username and password

You are here

Murine Melanoma